Erschienen in:
26.06.2017 | Hepatobiliary Tumors
The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres
verfasst von:
Fernando Pardo, MD, Bruno Sangro, MD, PhD, Rheun-Chuan Lee, MD, Derek Manas, MBBCh, FCS(SA), FRCSEd, Rohan Jeyarajah, MD, Vincent Donckier, MD, PhD, Geert Maleux, MD, PhD, Antonio D. Pinna, MD, PhD, Lourens Bester, M Med Rad, FRANZCR, FACP, David L. Morris, MD, PhD, David Iannitti, MD, Pierce K. Chow, MD, PhD, Richard Stubbs, MBChB, MD, FRCS (Eng), FRACS, Paul J. Gow, MD, Gianluca Masi, MD, Kevin T. Fisher, DO, FACOS, Wan Y. Lau, MD, DSc, FRCS, FRACS, FCSHK, FHKAM, Konstantinos Kouladouros, MD, Georgios Katsanos, MD, PhD, Giorgio Ercolani, MD, PhD, Fernando Rotellar, MD, PhD, José I. Bilbao, MD, PhD, Michael Schoen, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2017
Einloggen, um Zugang zu erhalten
Abstract
Background
Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres®; Sirtex).
Methods
Data were captured retrospectively at participating SIRT centers, with Y-90 resin microspheres, surgery (resection or transplantation), and follow-up for all eligible patients. Primary endpoints were perioperative and 90-day postoperative morbidity and mortality. Standard statistical methods were used.
Results
The study included 100 patients [hepatocellular carcinoma: 49; metastatic colorectal cancer (mCRC): 30; cholangiocarcinoma, metastatic neuroendocrine tumor, other: 7 each]; 36% of patients had one or more lines of chemotherapy pre-SIRT. Sixty-three percent of patients had comorbidities, including hypertension (44%), diabetes (26%), and cardiopathy (16%). Post-SIRT, 71 patients were resected and 29 received a liver transplant. Grade 3+ peri/postoperative complications and any grade of liver failure were experienced by 24 and 7% of patients, respectively. Four patients died <90 days postsurgery; all were trisectionectomies (mCRC: 3; cholangiocarcinoma: 1) and typically had one or more previous chemotherapy lines and presurgical comorbidities.
Conclusions
In 100 patients undergoing liver surgery after receiving SIRT, mortality and complication rates appeared acceptable given the risk profile of the recruited patients.